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Androgen deprivation (AD) is commonly used in neoadjuvant and adjuvant setting with prostate cancer (PC) radiotherapy. This
prospective study assessed whether cognitive functioning is impaired during 12 months of AD therapy. Longitudinal testing of 25
patients treated with AD and curative radiotherapy was undertaken at baseline, and at 6 and 12 months. CogniSpeed
r software was
used for measuring attentional performances. Other cognitive performances were evaluated using verbal, visuomotor and memory
tests. The Beck depression inventory was employed to evaluate depressive mood and EORTC QLQ-C30 for quality of life (QoL).
During longitudinal testing of the AD group, no impairment in cognitive performances was found. Instead, improvement was
observed in object recall (immediate, P¼0.035; delayed, Po0.001), and in semantic memory (P¼0.037). In QoL, impairment in
physical function was observed. Androgen deprivation of 12 months appears to be associated with preserved cognitive functioning,
although physical impairment occurs. These results have implications for counseling and psychosocial support of patients in the
context of treatment options in PC.
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Prostate cancer (PC) has become one of the most common cancers
among men in the Western world. Most patients are diagnosed
with potentially curable disease. During recent years, it has become
common practice to combine androgen deprivation (AD) with
radical radiotherapy in a neoþadjuvant setting, since this
approach has been shown to improve survival of patients with
poor prognosis (Bolla et al, 1997). A striking increase in the
incidence of PC with poor prognosis in men aged o60 years has
been reported (Post et al, 1999). A combined approach has been
suggested to reduce the mortality due to this disease (Demers et al,
2001). Androgen deprivation has also been proposed as an
alternative to watchful waiting for men with clinically localised
disease electing less aggressive management (Yang et al, 1998), and
AD is widely used as a means of preventing progression if local
therapies cannot be utilised for reasons of patient’s preference or
poor general condition (Gee, 1995).
Although AD is the treatment of choice in metastatic PC, there is
no international consensus on indications or treatment duration in
the use of neoþadjuvant treatment in PC. The indications for and
duration of AD used in connection with radical treatment call for
evidence-based recommendations. Any treatment of these patients
causing adverse effects should therefore be carefully monitored to
ensure that treatment-related effects do not exceed the disease-
related (Fransson et al, 2001). A common practice outside clinical
trials is to apply AD for 3–6 months, but treatments as long as
several years are also practised. The use of AD appears to be most
common in early-stage disease (T1–T2), as reported by Potosky
et al (2001), these being patients who are usually long-term
survivors in PC. At least 22000PC men each year in the US have
been estimated to receive hormonal therapy (Potosky et al 2001).
Androgen deprivation therapy for PC is known to affect the
quality of life (QoL) adversely, leading to increased fatigue, erectile
difficulties and decline in sexual function (Potosky et al, 2002).
Although cognitive complaints are not uncommon during AD
treatment (Green et al, 2002a,b), they have not hitherto been
systematically addressed in this patient group. There have been
suggestions that lowered testosterone level is associated with
impairment of cognitive functioning (O’Connor et al, 2001) and
that testosterone replacement therapy may improve certain
memory performances (Cherrier et al, 2001), but these studies
have addressed on healthy old men. Whether AD affects cognitive
functioning in newly diagnosed PC patients in any significant way
has not, to our knowledge, been previously reported. We
hypothesised that AD may have an impact on cognitive
performances in PC patients, especially on attention and memory,
because these functions are known to be sensitive to disease-
related and other kinds of stress effects (Barrett-Connor et al,
1999). A systematic study on cognitive functioning during 1 year of
AD treatment of PC patients was conducted to study quantitatively
the changes associated with this treatment.
PATIENTS AND METHODS
Patients
Extensive cognitive testing was undertaken on three occasions in
25 men receiving neoþadjuvant AD therapy for 12 months in
connection with radical radiotherapy for PC. The patients had to
fulfil at least two of the following criteria to be eligible for Received 13 January 2003; revised 29 April 2003; accepted 29 June 2003
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lhormonal treatment: tumour grade 42, Gleason 45 and Prostate-
specific antigen (PSA) 420. Only patients with newly diagnosed
PC requiring therapy were accepted. Eight patients (32%) had
performance status 0 and 17 patients (68%) status 1 as measured
by WHO criteria (Miller, 1981). World Health Organisation
(WHO) performance status 0 indicates full functioning with no
symptoms, and WHO 1 indicates normal performance status with
slight or occasional symptoms. Most of the patients had a T3
tumour (84%); there were two with T2 and two with T4 tumours,
and all represented grade 2–3 tumours. Their mean PSA at
diagnosis was 31ngl
 1 (s.d. 25.4). None of the patients developed
progressive disease during the 12-month study period.
The 52 healthy controls for baseline evaluation were voluntary
male participants who had no psychiatric or neurological disorders
or history of drug or alcohol abuse. Control group of normal
healthy men at baseline was used to comparison of basic cognitive
performances of the PC patient group. The patients and control
persons came from southwestern Finland and were matched for
distribution of age and education. The mean age of the patients
was 64.4 years (s.d. 6.5, range 49–75), and their mean education
8.9 years (s.d. 2.9, range 6–15). The mean age of the controls was
65.3 years (s.d. 6.6, range 46–77), education a mean of 8.5 years
(s.d. 2.1, range 6–15). Mini-mental state examination (MMSE) was
performed: for the patients, the mean score was 27.1 (s.d. 2.0,
range 21–29), and for the controls 28.0 (s.d. 1.4, range 25–30).
There was no statistically significant difference between the
groups; two patients who had a lower score than controls were
accepted.
To be eligible for neuropsychological testing, patients had to
meet the following inclusion criteria: (1) no evidence of
progressive or metastatic disease, (2) no history of neurological/
psychiatric signs or symptoms that might lead to deviant
neuropsychological test results, (3) no abuse of alcohol or drugs
and (4) the mother tongue being Finnish. Written informed
consent was obtained from all patients. The study was approved by
the joint ethical committee of Turku University Hospital and the
University of Turku.
Androgen deprivation therapy was started with flutamide given
for 4 weeks, and LHRH analogue (s.c. q 3 months four times) was
added after 2 weeks. Thus, AD therapy lasted 12 months.
Radiotherapy was given by the conformal technique using the
15MV photons/Varian Clinac 2100C/D linear accelerator (Varian
Inc. Palo Alto, CA, USA) to a mean tumour dose of 69Gy (s.d. 3.15,
range 61–77Gy). No fixation was used. Portal images were taken
with a Varian Portal Vision Mark 2 electronic portal imaging
device, integrated with Varis Vision 5.0 software, on average once a
week during about 7-week irradiation.
Neuropsychological testing
Neuropsychological testing was conducted using a cognitive test
battery at baseline, and at 6 and 12 months. Individuals in the
control group were examined only at baseline. The patients acted
as their own controls in the follow-up. The patients also attended
for clinical control check-up every 6 months after the onset of
therapy and were interviewed with regard to physical and mental
symptoms as experienced in daily life; PSA, Hb, serum creatinine
and liver enzymes were taken and QoL forms were filled on the
same occasions.
Our study was exploratory because there were no earlier reports
of antiandrogen effects on cognition in newly diagnosed PC
patients. The methods with corresponding references are explained
in full detail in the Appendix. We selected an extensive and
systematic test battery to evaluate basic verbal, visuomotor and
memory domains, and overall level of performances, as well as
cognitive speed and accuracy. Attentional domains and memory
can be expected to be particularly sensitive to both disease- and
treatment-related effects.
Cognitive processing was studied using CogniSpeed
r software,
planned to measure both automatic (well-learned) and controlled,
attention demanding processing. Automatic tasks consist of
recognition of familiar items (numbers and letters), whereas tasks
of controlled processing demand working memory or sustaining
attention. These functions may be most vulnerable to harmful
effects, such as depletion of hormone concentrations. Attention
and memory performances may reflect cognitive processing
efficiency also in everyday situations. One purpose of the study
was to find out whether there are cognitive domains sensitive to
impair in response to a year-lasting lack of androgens.
In order to utilise all information provided by test variables, we
used original data as continuous, not categorised variables. To
ensure that the subject had capacity to improvement, we evaluated
a subject’s overall impairment on verbal, visuomotor and memory
performances, using standard deviations of an independent norm
group. Most patients performed as controls on this deterioration
scale (range 0–18 points), which provides more information than
MMSE: for the controls the range was 0–3 (mean 0.80) and for the
patients 0–4 (mean 0.84) (Table 1). With regard to clinical
practice, it is always possible to compare an individual score in any
test, for example, in reaction time tests, with the means and
standard deviations of a healthy control group.
Quality of life
At the time of cognitive testing, the patients were also asked to fill
in EORTC QLQ-C30 forms (Fayers et al, 1997) completed with
sexual function items. These items in this study included questions
about level of sexual interest, ability to achieve and maintain
erection, gynaecomastia, spousal relationship and mood. Other
items asked respondents about overall physical or mental
discomfort, worry, role functioning, limitations in daily activities
and bother due to PC or treatments.
Statistical analyses
The data were summarised showing mean values and standard
errors (s.e.). the patients who had measurements at baseline and at
least at either of the two follow-up time points were included in the
analyses. Statistical comparisons of patients and controls at
baseline were made using two-sample t-test. Within the patient
groups, the comparisons of different time points were carried out
with analysis of variance for repeated measurements. The pairwise
post hoc comparisons of time points were conducted by Tukey’s
method. The analyses were performed using MIXED procedure in
the SAS System for Windows, release 6.12/1996. The MIXED
procedure offers a sophisticated tool for analysis of follow-up data
with possible missing data during follow-up (Littell et al, 1996).
P-values less than 0.05 were considered to be statistically
significant.
RESULTS
At baseline, the AD group performed at a lower level than the
control group, matched for distribution of age and education, in
immediate memory of digit span (P¼0.008), in visuomotor digit
symbol (P¼0.011) and in word fluency (P¼0.049). Comparisons
between controls and patients at baseline are shown in Tables 1
and 2.
Other performances in memory tests (semantic memory, visual
memory, word recall), in visuomotor block design or naming tests
did not differ between the groups. The depression scores were low
and did not differ. Further, the AD group performed more slowly
than the controls in the sustained attention vigilance task
(Po0.001), but the groups did not differ in the other reaction
time tasks or in the recognition task (Table 2). A comparison of the
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lAD group and controls in reaction time tests in different
attentional domains is presented in Figure 1.
During the period of 12 months on AD, some changes emerged
in memory performances compared to the baseline values
(Table 1). The patients improved their performances in episodic
memory (immediate recall of objects, P¼0.035, significant change
for the first 6 months and delayed recall Po0.001, significant
change for the whole test period) and in semantic memory
(similarities, P¼0.037, significant change for the latter half of the
test period (Figure 2). Other performances, including reaction
speed and accuracy in reaction time tests, remained unchanged
through the follow-up testings (Table 2). Beck depression scores
remained similar throughout the follow-up testings.
On the self-report QoL forms (Table 3) a significant worsening
of physical functioning was seen when the results of 12 months
were compared with that of baseline.
During the treatment, the patients expressed significantly more
suffering from fatigue, dyspnoea and diarrhoea compared to
baseline. No statistically significant changes were reported in the
case of emotional, social or cognitive functioning. Table 4 shows in
detail the development of changes in physical and emotional items.
Although the patients reported their sexual interest, male identity
and erectile function to decrease significantly during AD, they did
not feel more depressed nor did they indicate that their relation-
ship with their spouse suffered from their present condition more
than at baseline.
DISCUSSION
Since AD treatment is commonly used in PC, the objective of our
study was to investigate the effects of AD at 6 and 12 months on
cognitive function in PC patients with a view to helping the
clinician in decision-making and education of patients on
treatment effects. The current study showed some deficits in
verbal and visuomotor performances as well as sustained attention
of the patient group in comparison to controls. During AD
treatment, in spite of impaired physical function in these patients,
they showed significant improvement in some memory perfor-
mances and no cognitive impairments when AD treatment was
Table 1 Verbal, visuomotor and memory performances in patients (n¼25) and controls (n¼52): comparison at baseline, and testing of patients from










Similarities 19.9(0.39) 0.511 20.2 (0.64) 20.2 (0.65) 21.6 (0.66) 0.037 6o12
Digit span 10.9 (0.30) 0.008 9.5 (0.32) 10.1 (0.33) 10.5 (0.33) 0.062
Digit symbol 37.3 (1.25) 0.011 30.9 (2.03) 31.5 (2.07) 34.2 (2.05) 0.166
Block design 32.4 (1.12) 0.497 30.0 (1.73) 31.3 (1.74) 31.7 (1.75) 0.260
Object naming (s) 33.7 (1.23) 0.656 36.3 (2.23) 37.1 (2.29) 33.5 (2.27) 0.316
Object recall (immediate) 12.1 (0.32) 0.412 12.4 (0.45) 13.6 (0.47) 13.8 (0.46) 0.035 Bo6
Object recall (delayed) 10.1 (0.31) 0.927 10.4 (0.56) 11.9 (0.57) 12.3 (0.56) 0.001 Bo6;Bo12
Deterioration score 0.80 (0.28) 0.922 0.84 (0.25) 0.94 (0.26) 0.43 (0.26) 0.245
Verbal fluency
b 27.3 (2.36) 0.049 21.3 (1.08) 22.0 (1.10) 21.9 (1.08) 0.791
Picture naming
b 13.3 (0.58) 0.874 13.4 (0.31) 13.4 (0.32) 13.7 (0.31) 0.281
Word list recall
b 19.3 (1.26) 0.242 21.0 (0.78) 21.1 (0.80) 20.8 (0.79) 0.875
Benton, visual recognition (correct) 5.2 (0.25) 5.6 (0.26) 5.4 (0.26) 0.158
Visual span (Wechsler memory scale) 15.8 (0.61) 16.0 (0.62) 15.4 (0.62) 0.534
Mini-mental state 28.0 (0.20) 0.147 27.1 (0.40) 27.5 (0.40) 27.6 (0.40) 0.611
Beck depression score 2.7 (0.33) 0.780 2.8 (0.53) 2.5 (0.55) 2.2 (0.54) 0.753
B¼baseline; 6¼6 month-testing; s.e.¼standard error; s¼second; 12¼12 month-testing;
aTukey’s multiple comparison corrected.
bNumber of controls¼12.
Table 2 Cognitive speed and attention in patients ((n¼25) and controls (n¼52): comparison at baseline, and testing of patients from baseline through









282 (4.8) 0.427 291 (10.9) 311 (11.2) 324 (11.3) 0.061
2-CRT (ms) 506 (16.3) 0.545 534 (19.9) 547 (20.1) 532 (20.2) 0.391
2-CRT, errors 1.1 (0.22) 0.106 0.52 (0.17) 0.79 (0.18) 0.56 (0.18) 0.599
10-CRT (ms) 1002 (24.8) 0.056 1113 (48.5) 1134 (49.0) 1130 (49.6) 0.786
10-CRT, errors 0.4 (0.10) 0.534 0.60 (0.20) 0.62 (0.21) 0.81 (0.22) 0.717
Subtraction (ms) 1599 (64.4) 0.064 1968 (154.5) 2017 (155.8) 1871 (157.9) 0.334
Subtraction, errors 1.7 (0.25) 0.120 3.2 (0.80) 3.1 (0.81) 4.1 (0.83) 0.355
Subtraction time 597 (53.4) 0.116 855 (136.5) 917 (138.1) 740 (140.4) 0.220
Vigilance
a (ms) 463 (5.6) o0.001 509 (9.4) 501 (9.6) 504 (10.1) 0.579
Vigilance
a, errors 2.4 (0.48) 0.115 4.1 (0.76) 2.4 (0.79) 3.7 (0.85) 0.159
Recognition
Numbers
a (ms) 62.7 (2.91) 0.200 70.8 (3.14) 69.9 (3.43) 67.3 (3.35) 0.635
Letters
a (ms) 67.6 (3.06) 0.393 76.8 (4.17) 73.8 (4.40) 69.7 (4.37) 0.234
SE¼standard error; ms¼millisecond; RT¼reaction time; 2-CRT¼two-choice choice reaction time; 10-CRT¼10-choice reaction time.
aNumber of controls¼33.
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lgiven for up to 12 months. During 12-month testing of the AD
group, significant improvement was observed compared to base-
line values in episodic memory measures of object recall and in
semantic memory, whereas no impairment was found in any
cognitive performances evaluated, including cognitive speed in
reaction time tasks.
To minimise individual variability and learning effect in
reaction time tasks, there was a practice round preceding the
CogniSpeed
r subtests. The repeated measures of CogniSpeed
r
tests have shown a reliable and steady course over trials in healthy
persons and in the study with brain tumour patients (Lilja et al,
2001). Furthermore, the six tests of cognitive deterioration,
including verbal, visuomotor and memory tests, are sensitive to
cognitive impairment, even if the same versions are repeated
(Kujala et al, 1997). Learning effects normally occur in free recall
tasks in repeated measurements. We do not propose that there
could not be improvement in performances of controls, if tested,
because learning effects normally occur in free recall tasks in
repeated measurements. Learning effect can be considered a
positive sign of one’s capacity to utilise experience rather than a
negative source of error.
Androgen deprivation therapy for PC is known to affect the QoL
adversely, leading to increased fatigue, erectile difficulties and
declines in sexual functioning (Lubeck et al, 2001). The duration of
AD in clinical practice varies from 3 months to 3 years and even
longer. The present study set-up was motivated by the common
practice of using AD in the treatment of early-stage PC outside
clinical trials. We chose to test 12 months of treatment in view of
superior effects shown compared to shorter (Gleave et al, 2001),
and avoided longer treatment in order to delay the development of
hormone-resistant disease (Newling, 2000).
We focused on effects of hormonal treatment on attention and
information processing as well as memory function as these
domains of cognition are considered vulnerable to changes in
sexual hormone level (Barrett-Connor et al, 1999). In the literature,
there are some indications that androgen treatment may modulate
aspects of cognitive performance (Wolf et al, 2000). It has also
been suggested that testosterone replacement therapy may have a
positive effect on cognition, in particular on improved spatial and
verbal memory in healthy older men (O’Connor et al, 2001). This is
partly in agreement with the present results, which showed
selective improvement in episodic and semantic memory mea-
sures, whereas attention and information processing speed
remained unchanged through the treatment period. On the other
hand, decreased testosterone levels may be associated with
impaired cognition in aging men (Cherrier et al, 2001). In the
present study, the patients performed some tasks at lower level
than the control persons of similar age and education, when the
groups were compared at baseline before the start of antiandrogen
therapy. Thus, this impairment may refer to disease-related rather
than to more specific effects. Longitudinal cognitive stability and
improvements may suggest some positive hormonal influence on
brain functioning.
We recognise some limitations in the interpretation of our
results. We used normal controls at baseline as a reference group
for the PC patients. However, the groups were matched for basic
characteristics: they were of similar age and education, with no
major diseases. In the longitudinal study, the effect of AD
treatment on cognition was evaluated using the patient’s own
baseline values. This strengthens the interpretation of results,
while elderly PC patients are a heterogenous patient group with
often several comorbidities that could affect the results of cognitive
tests. Our results with similar pattern of cognitive testing with
patients treated with curative radiotherapy at the same dose level
as the study patients without AD resulted in no statistically





















Figure 1 Cognitive performance speed at baseline in reaction time tasks




























Figure 2 Cognitive performance of patients during AD therapy from
baseline through 6 and 12 months in three memory tests; statistically
significant improvement, marked as *.
Table 3 Physical scale values during 12 months of androgen deprivation
expressed as means and standard errors (s.e.)
Baseline 6 months 12 months
Function scales Mean (s.e.) Mean (s.e.) Mean (s.e.) P-value
Physical 87.1 (4.29) 79.3 (4.05) 77.2 (4.52) 0.0004
Cognitive 89.2 (2.21) 86.5 (3.21) 86.8 (2.66) 0.3451
Emotional 82.4 (3.35) 82.7 (3.58) 79.9 (3.76) 0.5919
Social 94.1 (1.98) 87.1 (2.99) 86.8 (4.33) 0.2098
Role functioning 95.7 (2.40) 98.2 (1.79) 95.0 (2.79) 0.3255
Feeling sick 1.07 (0.05) 2.42 (0.18) 2.55 (0.95) o0.0001
EORTC¼European Organization for Research and Treatment of Cancer. Higher
score means better functioning, scale 0–100.
Table 4 Comparison of selected quality of life items during 12 months of
androgen deprivation expressed as means and standard errors (s.e)
Symptom Baseline 6 months 12 months
scales/items Mean (s.e.) Mean (s.e.) Mean (s.e.) P-value
Fatigue 14.3 (3.08) 19.7 (4.10) 20.5 (4.30) 0.044
Dyspnoea 8.57 (3.70) 13.6 (3.67) 17.2 (4.57) 0.030
Insomnia 21.6 (4.42) 34.6 (4.87) 34.5 (5.36) 0.1071
Diarrhoea 4.76 (2.00) 17.3 (5.15) 17.2 (4.26) 0.001
Erectile dysfunction 221 (1.07) 3.08 (1.06) 3.32 (0.86) 0.0002
Gynaecomastia 1.23 (0.08) 1.46 ( 0.15) 1.46 (0.12) 0.0005
Libido 1.83 (0.16) 3.00 (0.20) 3.10 (0.18) o0.0001
Male identity 1.96 (0.96) 3.28 (0.74) 3.00 (1.07) 0.0011
Depressive mood 1.77 (0.16) 1.54 (0.13) 1.77 (0.16) 0.8567
Spouse relationship 1.32 (0.10) 1.64 (0.18) 1.48 (0.16) 0.2332
Urinary frequency 2.25 (0.89) 2.15 (0.73) 2.00 (0.82) 0.0425
a
aOther items worsened, this item improved significantly.
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lIn concord with the observations of Van Dam et al (1998) in
chemotherapy-treated breast cancer patients, we observed that
patients complained, for example, of depressive mood and similar
discomforts, although these were not confirmed by the Beck
depression results. It has been proposed that objective test results
and subjective reports of patients regarding their cognitive
functioning and mood are not always related; there has been no
relationship between the self-reported difficulties and the perfor-
mance of patients in objective tests (Cull et al, 1966; Ly et al, 2001).
Furthermore, PC patients with nonlocal cancer randomised either
to AD or follow-up did not differ in subjective cognitive function
(Green et al, 2002a,b). Subjective reports have been found to be
related to anxiety and depression, being indicative more of
emotional distress than cognitive deficits (Van Dam et al, 1998;
Ly et al, 2001).
In comparison to a report by Fransson et al (2001), who
observed decreased QoL in the social functioning of PC patients
treated with radiotherapy only, our patients did not evince this,
although the forms they filled in were similar. The difference is in
evaluation time, which was over 3 years in Fransson’s series. The
deterioration in physical function reported by our patients was in
line with the previous results (Lubeck et al, 2001).
CONCLUSION
Healthy PC patients treated with AD in connection with curative
radiotherapy maintain their cognitive functioning. Cognitive
deficits found at baseline were associated with disease severity
rather than with treatment-related factors. The documentation of
cognitive function has substantial implications for informed
patient’s support when hesitating between treatment options. A
longer follow-up study with cognitive assessment is needed if AD is
extended for several years, and further studies are needed to clarify
the effects of AD in patients with severe comorbidity.
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APPENDIX
Cognitive tests were used to measure verbal, visuomotor and
memory performances, as well as cognitive processing in different
attentional domains. The investigations were performed in 3-h
sessions, with short breaks if needed, by two experienced
psychologists.
Two verbal and two visuomotor subtests (Wechsler, 1955) were
administered: similarities, digit span, digit symbol and block
design. The verbal fluency test comprised generating orally names
of animals during 1min. In the picture-naming test, the subject
had to name 15 line drawings presenting concrete objects.
Episodic memory was investigated using four tests: (1) naming
time, immediate and delayed (after 1h) recall of 20 common
objects (Lilja et al, 2001); (2) the word list recall consisted of 10
words, which the subject was instructed to read when shown to
him/her one at a time, and there were three trials for immediate
recall (Lezak, 1995); (3) the visual recognition test consisted of
seven designs (form C), shown one at a time for 10s (Benton,
1963). After the study phase, the set was removed and the subject
had to point to the right design among four alternatives; (4) visual
memory span (Wechsler, 1987) comprised tests of tapping squares
on a card in a given order. The total score was the sum of correctly
repeated series forward and backward.
The overall cognitive deterioration score consisted of deteriora-
tion points in six tasks addressing memory, visuomotor and verbal
domains (similarities, digit span, digit symbol, block design,
naming time and immediate recall of 20 objects). The results on
these tests were rescored based on our earlier results obtained by
healthy subjects. The subjects received one deterioration point if
their performance in any of the tests was below 1.5s.d. compared
to the norms, two points if below 2s.d., and three points if below
3s.d. The maximum deterioration score was thus 18 points (Kujala
et al, 1994).
To rule out severe cognitive impairment, the MMSE was
administered (Folstein et al, 1975); the cutoff was set as 21 points.
The Beck depression inventory was administered to evaluate
depressive mood (Beck et al, 1974).
The CogniSpeed
r software was used to measure the speed and
accuracy of automatic and controlled cognitive processing (Kujala
et al, 1994; Revonsuo et al, 1995). Reaction times (RTs) were
measured in milliseconds (ms) in correct responses, and the error
scores were recorded. In each CogniSpeed
r test, a practice session
was held before the final test round, and the subject was instructed
to respond as quickly as possible. The final test rounds comprised
40 items.
Automatic processing was studied with a task involving
recognition thresholds of well-learned targets (four numbers and
six letters). A letter ‘X’ shown in the middle of the screen was
replaced briefly by the target. The first presentation time of 14ms
was increased stepwise in 14-ms steps, until the target was
identified.
Controlled processing addressing different attentional functions,
was evaluated in series of RT tasks, which became more difficult
step by step. In the simple reaction time (SRT) test, the subject
had to press the ‘0’ key every time the target ‘0’ appeared on the
screen with a random delay ranging from 1 to 4s. In the choice
RT tests, the stimuli appeared in random order. In the two-choice
(2-CRT) test, either ‘1’ or ‘2’ appeared in the middle of the screen
and the subject was instructed to press the corresponding key. In
the 10-choice (10-CRT) test, the numbers 0–9 appeared in the
middle of the screen, and the subject had to press the
corresponding number. The subtraction test, which requires
concentrating attention and working memory, was identical to
the 10-CRT test, but the instruction given to the subject was
different: the number appearing on the screen had to be subtracted
from nine, and the key corresponding to the remainder pressed.
The subtraction time was the difference in the RTs between the
subtraction test and the 10-CRT test, with similar perceptual and
motor requirements. Thus, subtraction time represented conscious
working memory components in tasks involving relatively high
attentional demands.
The vigilance test of letter cancellation measured sustaining
attention. This was a monotonous task of 15min, with target
events occurring at a relatively slow rate and in random order.
There were two target letters (Y, L) appearing with a probability of
20% among all 600 letters; the presentation time was 500ms and
the interval between letters 1000ms.
Cognition in prostate cancer
E Salminen et al
976
British Journal of Cancer (2003) 89(6), 971–976 & 2003 Cancer Research UK
C
l
i
n
i
c
a
l